South Korea's exports of packaged traditional chicken soup reached US$4.82 million over the January-April period, jumping by 82.2 percent from last year.
There is a growing demand for ready-to-eat products around the globe due to the pandemic-led lockdowns.
The United States had the biggest appetite for traditional chicken soup or samyetang, accounting for $2.1 million packages, trailed by Japan with $1.19 million, according to the data compiled by the Korea Agro-Fisheries & Food Trade Corp.
Canada and Hong Kong followed $500,000 each.
South Korea only started to ship the products to Canada in February.
South Korea also ships the products to China, Vietnam, and the United Arab Emirates and three other countries.
The latest increase was due to the growing demand for packaged foodstuffs as people are forced to stay inside their homes. The food's health aspect also contributed to boosting sales.
Samgyetang contains a whole young chicken, ginseng, garlic, and sticky rice.
South Korea's exports of processed foodstuffs rose 46.3 percent in April to $294 million, with outbound shipments of instant noodles soaring 52.3 percent.


Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks
SK Hynix Shares Surge on Record $28.6 Billion Buyback
BofA Sees Micron EPS Topping $230 by 2030, Backs Major Stock Upside
Shein Targets $26B-$27B Valuation for Hong Kong IPO
Google to Buy Spirit Airlines Business Data for $10 Million to Train AI
Coty Revenue Beats Estimates as Beauty Demand Holds Firm
Standard Chartered Expands Hedge Fund Access for Wealth Clients
REPAY Stock Rises After Visa Platform Connect Collaboration
Alibaba Sells Lingxi Games for Over $1.5 Billion Amid AI Push
Anthropic Eyes $10B-Plus Credit Line Ahead of Potential IPO
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut
OpenAI Tightens AI Safety Monitoring After Security Incidents
Alphabet Eyes First Australian Dollar Bond as AI Spending Drives Funding Push
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead 



